---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-24-000242"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:40:42.906347+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B

## Summary
- Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.
- Reported EPS $1.07; non-GAAP EPS $1.18, both including $3.08 acquired IPR&D charges.
- Mounjaro and Zepbound drove volume growth; non-incretin revenue up 17% ex-divestiture.
- FY 2024 revenue guidance raised to $45.4-$46.0B; EPS guidance $12.05-$12.55 reported, $13.02-$13.52 non-GAAP.
- Positive Phase 3 data for tirzepatide (94% diabetes risk reduction) and donanemab (reduced ARIA-E).

## SEC filing metadata
- accession: 0000059478-24-000242
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947824000242/0000059478-24-000242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947824000242/lly-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-24-000242
- JSON: https://secwatch.observer/filing/0000059478-24-000242.json
- Plain text: https://secwatch.observer/filing/0000059478-24-000242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.